「prioritization」の検索結果

Estimates SNP heritability and partitions it across functional annotations, cell types, and loci from GWAS summary statistics or individual-level genotypes. Implements LDSC, stratified LDSC with the baseline-LD model, Finucane 2018 cell-type prioritization, LDAK SumHer, HDL, HESS local heritability, BOLT-REML, GCTA-GREML, graphREML, and Popcorn cross-population genetic correlation. Use when computing total h2_SNP from summary stats, partitioning heritability across functional categories, prioritizing trait-relevant tissues or cell types from ENCODE/Roadmap chromatin marks, reconciling LDSC vs LDAK enrichment estimates, computing local heritability with HESS, estimating genetic correlation between traits, or producing publication-grade enrichment with calibrated sensitivity to model assumptions.

日本語の概要は準備中です。原文の説明を表示しています。

Use when ranking competing initiatives for a roadmap, breaking a tie between two features, or auditing a backlog for hidden low-value work via Reach × Impact × Confidence ÷ Effort.

日本語の概要は準備中です。原文の説明を表示しています。

[Project Management] Use when you need to capture ideas, manage product backlogs, apply prioritization frameworks (RICE, MoSCoW), and facilitate stakeholder communication.

日本語の概要は準備中です。原文の説明を表示しています。

Qualifies and scores B2B prospects against a supplied ideal customer profile. Use when the user provides a lead list, company records, prospect data, or qualification criteria and wants prioritization, fit analysis, or disqualification reasons.

日本語の概要は準備中です。原文の説明を表示しています。

Ranks companies or accounts by strategic relevance and opportunity. Use when the user provides accounts and wants a priority score, tier, rationale, risks, and next action.

日本語の概要は準備中です。原文の説明を表示しています。

Map application security findings to OWASP Top 10 categories and generate remediation checklists. Use for normalized AppSec review outputs and category-level prioritization.

日本語の概要は準備中です。原文の説明を表示しています。

Structured decision making: Pro/Con matrix, weighted scoring, decision tree, scenario analysis, and Eisenhower matrix.

日本語の概要は準備中です。原文の説明を表示しています。

Ordnet Büroaufgaben, Korrespondenz und Fristen ohne Bindung an eine bestimmte Office-App.

日本語の概要は準備中です。原文の説明を表示しています。

Shape FriendlyBet product decisions, MVP scope, user stories, tournament flows, multi-sport expansion, pool mechanics, social competition loops, and feature prioritization. Use when planning what FriendlyBet should build, cut, sequence, or validate, especially for new sports, prediction formats, pool flows, leaderboards, sharing, or product strategy.

日本語の概要は準備中です。原文の説明を表示しています。

Use when working with Codescene — codeScene behavioral code analysis including code health scoring, hotspot detection, change coupling analysis, and PR integration for code quality gates. Use when configuring CodeScene for codebase visualization, technical debt prioritization, and automated code review feedback.

日本語の概要は準備中です。原文の説明を表示しています。

Use when working with Wiz — wiz cloud security posture management. Covers cloud security posture analysis, vulnerability prioritization, attack path analysis, compliance assessment, container security, and resource inventory. Use when assessing cloud security posture, investigating attack paths, prioritizing vulnerabilities, or auditing cloud compliance.

日本語の概要は準備中です。原文の説明を表示しています。

Use for mission: define, prioritize, --tick, progress, scan.

日本語の概要は準備中です。原文の説明を表示しています。

Advanced vulnerability analysis principles. OWASP 2025, Supply Chain Security, attack surface mapping, risk prioritization.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end post-GWAS causal inference pipeline orchestrating heritability partitioning, genetic correlation, Mendelian randomization with CHP-aware sensitivity (CAUSE / LHC-MR), colocalization, fine-mapping with SuSiE / FOCUS, mediation, TWAS triangulation, cis-pQTL drug-target MR, effector-gene prioritization (L2G / PoPS / cS2G), and GenomicSEM common-factor GWAS. Use when triangulating causal inference across multiple complementary methods, prioritizing tissues via stratified LDSC, nominating or de-risking drug targets, mapping a lead SNP to a candidate effector gene, modeling shared genetic architecture across correlated traits, or producing a STROBE-MR-compliant publication-grade evidence battery from GWAS summary statistics.

日本語の概要は準備中です。原文の説明を表示しています。

Transform GWAS signals into drug targets and repurposing opportunities. Connects GWAS-significant loci to causal genes via fine-mapping/eQTL, then to druggable proteins via DGIdb/OpenTargets, then to existing drugs via ChEMBL. Use for GWAS-to-target hypothesis generation, druggable-fraction analysis of disease loci, and human-genetics-validated drug-repurposing prioritization.

日本語の概要は準備中です。原文の説明を表示しています。

Quantitative drug-target validation pipeline. Scores druggability, selectivity, safety profile, ADMET feasibility, and structural tractability with a composite Target Validation Score (0-100) and GO/NO-GO recommendation. Use for go/no-go decisions on a target before commit-to-medchem, target prioritization across a list, and target-deselection rationale.

日本語の概要は準備中です。原文の説明を表示しています。

Medicinal chemistry filters. Apply drug-likeness rules (Lipinski, Veber), PAINS filters, structural alerts, complexity metrics, for compound prioritization and library filtering.

日本語の概要は準備中です。原文の説明を表示しています。

Turn product requirements into scoped tasks with dependencies and acceptance criteria. Use for implementation planning and prioritization.

日本語の概要は準備中です。原文の説明を表示しています。

Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.

日本語の概要は準備中です。原文の説明を表示しています。

Maps GWAS-implicated loci to candidate effector (causal) genes by integrating variant-to-gene (V2G) features via Open Targets L2G (Mountjoy 2021), MAGMA gene-based association (de Leeuw 2015), FUMA SNP2GENE, cS2G combined SNP-to-gene scores (Gazal 2022), Polygenic Priority Scores (PoPS, Weeks 2023), FLAMES, INQUISIT, DEPICT, and enhancer-gene predictors (ABC, ENCODE-rE2G). Use when narrowing a GWAS lead locus to a candidate causal gene, picking between proximity, eQTL-based, and similarity-based prioritizers, integrating multi-evidence streams (fine-mapping, colocalization, ABC enhancer-gene, distance, chromatin), reconciling discordant L2G vs PoPS calls, prioritizing tissue-specific eQTL evidence, or triangulating across at least three independent lines of evidence for a publication-grade effector-gene nomination.

日本語の概要は準備中です。原文の説明を表示しています。

Estimate SNP heritability and partition it across functional annotations, cell types, and loci from GWAS summary statistics or individual-level genotypes. Implements LDSC, stratified LDSC with the baseline-LD model, Finucane 2018 cell-type prioritization, LDAK SumHer, HDL, HESS local heritability, BOLT-REML, GCTA-GREML, graphREML, and Popcorn cross-population genetic correlation. Use when computing total h2_SNP from summary stats, partitioning heritability across functional categories, prioritizing trait-relevant tissues or cell types from ENCODE/Roadmap chromatin marks, reconciling LDSC vs LDAK enrichment estimates, computing local heritability with HESS, estimating genetic correlation between traits, or producing publication-grade enrichment with calibrated sensitivity to model assumptions.

日本語の概要は準備中です。原文の説明を表示しています。

Strategic advisor for Evvo Labs business decisions. Use when Vince asks for strategic advice, business opinions, market entry decisions, pricing strategy, product prioritization, resource allocation, partnership evaluation, competitive positioning, or any question about what Evvo should do next. Applies 5 frameworks: VRIO (competitive advantage), Value Stick (pricing/margin), Blue Ocean (market positioning), McKinsey Horizons (resource allocation), Strategy Diamond (initiative planning). Always read references/evvo-strategy.md before advising.

日本語の概要は準備中です。原文の説明を表示しています。

Framework-directable information security risk assessment. Identifies threats, evaluates likelihood/impact via a 3x3 matrix, maps findings to any compliance framework, and recommends risk treatment options with prioritization guidance.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluate strategic options by NPV vs ease of implementation. Use for project prioritization, resource allocation, and strategic decision making.

日本語の概要は準備中です。原文の説明を表示しています。